If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
You are now leaving the LillyMedical.com Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party Web sites. We encourage you to read the privacy policy of every Web site you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Radiation dosimetry and pharmacokinetics of florbetapir (18F) in Japanese subjects
Published Date: May 28, 2019
Publication Link
Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale
Published Date: July 11, 2018
Publication Link
Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer’s Disease With Amyloid-PET
Published Date: April 9, 2019
Publication Link
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
Published Date: March 28, 2018
Publication Link
Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia
Published Date: August 11, 2017
Publication Link
Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer’s Disease With Amyloid-PET
Published Date: April 9, 2019
Publication Link
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
Published Date: March 28, 2018
Publication Link
Effectiveness of Florbetapir PET Imaging in Changing Patient Management
Published Date: August 5, 2017
Publication Link
Effectiveness of Florbetapir PET Imaging in Changing Patient Management
Published Date: August 5, 2017
Publication Link
Cymbalta
Full Prescribing InformationNo Publications.
No Publications.
Relationship Between Pain Reduction and Improvement in Health-Related Quality of Life in Patients with Knee Pain Due to Osteoarthritis Receiving Duloxetine: Exploratory Post Hoc Analysis of a Japanese Phase 3 Randomized Study
Published Date: January 20, 2020
Publication Link
Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data
Published Date: April 23, 2019
Publication Link
Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy
Published Date: April 5, 2019
Publication Link
Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial
Published Date: March 21, 2019
Publication Link
An Open-Label, 52-Week, Phase III Trial of Duloxetine in Japanese Patients with Chronic Low Back Pain
Published Date: March 11, 2019
Publication Link
Efficacy of duloxetine by prior NSAID use in the treatment of chronic osteoarthritis knee pain: A post hoc subgroup analysis of a randomized, placebo-controlled, phase 3 study in Japan
Published Date: August 18, 2018
Publication Link
A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis
Published Date: April 18, 2018
Publication Link
Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine
Published Date: September 25, 2017
Publication Link
Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
Published Date: September 19, 2017
Publication Link
Assessment of direct analgesic effect of duloxetine for chronic low back pain: post hoc path analysis of double-blind, placebo-controlled studies
Published Date: June 1, 2017
Publication Link
Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study
Published Date: January 20, 2017
Publication Link
Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy
Published Date: April 5, 2019
Publication Link
Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
Published Date: September 26, 2018
Publication Link
Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, double-blind, noninferiority comparative study with pregabalin
Published Date: September 13, 2018
Publication Link
Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East
Published Date: September 30, 2017
Publication Link
Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine
Published Date: September 25, 2017
Publication Link
Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
Published Date: September 19, 2017
Publication Link
An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis
Published Date: August 4, 2017
Publication Link
An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
Published Date: August 4, 2017
Publication Link
Assessment of direct analgesic effect of duloxetine for chronic low back pain: post hoc path analysis of double-blind, placebo-controlled studies
Published Date: June 1, 2017
Publication Link
Emgality
Full Prescribing InformationPopulation Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
Published Date: September 4, 2019
Publication Link
Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies
Published Date: September 17, 2018
Publication Link
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
Published Date: October 17, 2017
Publication Link
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Galcanezumab, a Monoclonal Antibody to Calcitonin Gene-Related Peptide, in Healthy Japanese and Caucasian Subjects
Published Date: August 19, 2017
Publication Link
Response to ‘Do different treatment strategies of galcanezumab have similar effect on migraine?’
Published Date: February 12, 2020
Publication Link
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
Published Date: January 17, 2020
Publication Link
Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
Published Date: September 4, 2019
Publication Link
Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
Published Date: June 7, 2019
Publication Link
A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
Published Date: March 27, 2019
Publication Link
Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis
Published Date: October 15, 2018
Publication Link
Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab
Published Date: October 5, 2018
Publication Link
CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial
Published Date: September 19, 2018
Publication Link
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
Published Date: May 28, 2018
Publication Link
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
Published Date: December 18, 2017
Publication Link
Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
Published Date: April 27, 2020
Publication Link
Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
Published Date: April 21, 2020
Publication Link
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
Published Date: February 12, 2020
Publication Link
Response to ‘Do different treatment strategies of galcanezumab have similar effect on migraine?’
Published Date: February 12, 2020
Publication Link
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
Published Date: January 17, 2020
Publication Link
Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
Published Date: December 27, 2019
Publication Link
Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies
Published Date: November 13, 2019
Publication Link
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
Published Date: November 11, 2019
Publication Link
Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
Published Date: November 6, 2019
Publication Link
Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
Published Date: November 6, 2019
Publication Link
Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
Published Date: September 4, 2019
Publication Link
Erratum: Correction to 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
Published Date: July 11, 2019
Publication Link
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
Published Date: July 11, 2019
Publication Link
Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
Published Date: July 3, 2019
Publication Link
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
Published Date: June 28, 2019
Publication Link
Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure
Published Date: June 3, 2019
Publication Link
Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
Published Date: April 3, 2019
Publication Link
A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
Published Date: March 27, 2019
Publication Link
Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality‐of‐Life Questionnaire Version 2.1 Electronic Patient‐Reported Outcome in Patients With Episodic and Chronic Migraine
Published Date: March 12, 2019
Publication Link
Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Published Date: March 1, 2019
Publication Link
Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
Published Date: December 29, 2018
Publication Link
Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies
Published Date: November 21, 2018
Publication Link
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Published Date: November 16, 2018
Publication Link
Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
Published Date: November 13, 2018
Publication Link
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
Published Date: November 9, 2018
Publication Link
100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
Published Date: October 21, 2018
Publication Link
Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies
Published Date: September 17, 2018
Publication Link
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Published Date: May 31, 2018
Publication Link
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial
Published Date: May 29, 2018
Publication Link
No Publications.
Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol
Published Date: January 16, 2020
Publication Link
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study
Published Date: November 20, 2019
Publication Link
Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
Published Date: January 14, 2020
Publication Link
Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
Published Date: January 14, 2020
Publication Link
Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
Published Date: February 24, 2020
Publication Link
Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
Published Date: November 19, 2019
Publication Link
Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies
Published Date: September 30, 2019
Publication Link
Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
Published Date: August 29, 2019
Publication Link
Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
Published Date: August 21, 2019
Publication Link
Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)
Published Date: August 13, 2019
Publication Link
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
Published Date: July 24, 2019
Publication Link
Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
Published Date: July 3, 2019
Publication Link
Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
Published Date: July 3, 2019
Publication Link
Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials
Published Date: June 1, 2019
Publication Link
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Published Date: May 28, 2019
Publication Link
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
Published Date: December 11, 2018
Publication Link
No Publications.
Strattera
Full Prescribing InformationNo Publications.
Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine
Published Date: May 5, 2017
Publication Link
Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine
Published Date: May 5, 2017
Publication Link
Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study
Published Date: January 6, 2017
Publication Link
Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial
Published Date: February 1, 2017
Publication Link
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST